November 18th, 2026NATALEE, DeLLphi-305, INTerpath-001, and LITESPARK-012 Headline Key Oncology Data From ESMO 2026Experts weigh in on standout breast cancer, lung cancer, melanoma, and kidney cancer data presented at the 2026 ESMO Congress.Read more
November 15th, 2026Five Under 5: Top Oncology Videos for the Week of 11/8The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.Read more
November 14th, 2026The OncFive: Top Oncology Articles for the Week of 11/8The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.Read more
November 18th, 2026Elticertinib Receives FDA Fast Track Designation in EGFR Exon 20–Mutated NSCLCThe FDA granted fast track designation to elticertinib for pretreated EGFR exon 20 insertion–mutated NSCLC.Read more
November 18th, 2026Longitudinal Community Training Helps Prepare Oncology Fellows for Their Future CareersDeepa Rangachari, MD, discusses community oncology training, goal-concordant mentorship, genomic fluency, and multidisciplinary care.Read more
November 18th, 2026Updated KANDLELIT-001 Data Show Durable Responses With Frontline Calderasib Plus Pembrolizumab in KRAS G12C–Mutated NSCLCLonger follow-up of KANDLELIT-001 supports frontline calderasib plus pembrolizumab in KRAS G12C–mutated metastatic non–small cell lung cancer.Read more
November 17th, 2026Sintilimab Receives Positive CHMP Opinion for First-Line Nonsquamous NSCLCThe CHMP backed sintilimab plus chemotherapy in NSCLC; the FDA issued a complete response letter for the regimen in 2022.Read more
November 17th, 2026Quality Improvement and EGFR-Mutant Lung Cancer Survivorship Research Help Shape Fellowship TrainingChristine Ann Garcia, MD, MPH, discusses error review in fellowship training, survivorship in EGFR+ lung cancer, and nontraditional career paths.Read more